A Modification of Simon's Optimal Design for Phase II Trials When the Criterion Is Median Sample Size

作者: John J. Hanfelt , Rebecca S. Slack , Edmund A. Gehan

DOI: 10.1016/S0197-2456(99)00028-8

关键词:

摘要: Abstract We present a modification to Simon's optimal design for phase II trials in which the objective is minimize median sample size rather than expected when true response rate poor p = 0 . argue that modified may be preferred smaller institutions focus on single or small number of large program trials. Control Clin Trials 1999;20:555–566

参考文章(8)
Peter F. Thall, Richard Simon, Practical Bayesian guidelines for phase IIB clinical trials. Biometrics. ,vol. 50, pp. 337- 349 ,(1994) , 10.2307/2533377
Richard Simon, Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. ,vol. 10, pp. 1- 10 ,(1989) , 10.1016/0197-2456(89)90015-9
Lisa Garnsey Ensign, Edmund A. Gehan, Douglas S. Kamen, Peter F. Thall, An optimal three-stage design for phase II clinical trials Statistics in Medicine. ,vol. 13, pp. 1727- 1736 ,(1994) , 10.1002/SIM.4780131704
James E.Herndon II, A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials Controlled Clinical Trials. ,vol. 19, pp. 440- 450 ,(1998) , 10.1016/S0197-2456(98)00012-9
Stephanie J. Green, Steve Dahlberg, Planned versus attained design in phase II clinical trials. Statistics in Medicine. ,vol. 11, pp. 853- 862 ,(1992) , 10.1002/SIM.4780110703
L. Mariani, E. Marubini, Design and analysis of phase II cancer trials: A review of statistical methods and guidelines for medical researchers International Statistical Review. ,vol. 64, pp. 61- 88 ,(1996) , 10.2307/1403424
B. Leyland-Jones, S. Marsoni, R. Simon, R. E. Wittes, M. De Rosa, D. Hoth, Clinical drug development: an analysis of phase II trials, 1970-1985. Cancer treatment reports. ,vol. 71, pp. 71- 80 ,(1987)